You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
AstraZeneca
Baxter
Harvard Business School
Merck

Last Updated: December 5, 2023

AURYXIA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Auryxia, and when can generic versions of Auryxia launch?

Auryxia is a drug marketed by Keryx Biopharms and is included in one NDA. There are fourteen patents protecting this drug.

This drug has one hundred and twenty-two patent family members in twenty-three countries.

The generic ingredient in AURYXIA is ferric citrate. There are twenty drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ferric citrate profile page.

DrugPatentWatch® Generic Entry Outlook for Auryxia

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 18, 2024. This may change due to patent challenges or generic licensing.

There have been six patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Try a Trial

Drug patent expirations by year for AURYXIA
Drug Prices for AURYXIA

See drug prices for AURYXIA

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for AURYXIA
Generic Entry Date for AURYXIA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for AURYXIA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Akebia TherapeuticsPhase 3
USRC Kidney ResearchPhase 3
USRC Kidney ResearchPhase 4

See all AURYXIA clinical trials

Pharmacology for AURYXIA

US Patents and Regulatory Information for AURYXIA

AURYXIA is protected by fourteen US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of AURYXIA is ⤷  Try a Trial.

This potential generic entry date is based on patent ⤷  Try a Trial.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting AURYXIA

Ferric citrate dosage forms
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: CONTROL OF SERUM PHOSPHORUS LEVELS

Ferric organic compounds, uses thereof and methods of making same
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: CONTROL OF SERUM PHOSPHOROUS LEVELS

Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Ferric organic compounds, uses thereof and methods of making same
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: CONTROL OF SERUM PHOSPHOROUS LEVELS

Ferric organic compounds, uses thereof and methods of making same
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Ferric organic compounds, uses thereof and methods of making same
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Ferric organic compounds, uses thereof and methods of making same
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: CONTROL OF SERUM PHOSPHOROUS LEVELS

Ferric organic compounds, uses thereof and methods of making same
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: CONTROL OF SERUM PHOSPHOROUS LEVELS

Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: CONTROL OF SERUM PHOSPHOROUS LEVELS

Ferric organic compounds, uses thereof and methods of making same
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: CONTROL OF SERUM PHOSPHOROUS LEVELS

Ferric citrate dosage forms
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: CONTROL OF SERUM PHOSPHOROUS LEVELS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Keryx Biopharms AURYXIA ferric citrate TABLET;ORAL 205874-001 Sep 5, 2014 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Keryx Biopharms AURYXIA ferric citrate TABLET;ORAL 205874-001 Sep 5, 2014 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Keryx Biopharms AURYXIA ferric citrate TABLET;ORAL 205874-001 Sep 5, 2014 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Keryx Biopharms AURYXIA ferric citrate TABLET;ORAL 205874-001 Sep 5, 2014 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Keryx Biopharms AURYXIA ferric citrate TABLET;ORAL 205874-001 Sep 5, 2014 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Keryx Biopharms AURYXIA ferric citrate TABLET;ORAL 205874-001 Sep 5, 2014 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for AURYXIA

See the table below for patents covering AURYXIA around the world.

Country Patent Number Title Estimated Expiration
South Korea 100464504 ⤷  Try a Trial
Taiwan I754951 ⤷  Try a Trial
European Patent Office 1978807 MÉTHODE DE TRAITEMENT DE NÉPHROPATHIE CHRONIQUE (METHOD OF TREATING CHRONIC KIDNEY DISEASE) ⤷  Try a Trial
Canada 2272711 PROCEDES DE TRAITEMENT DE L'INSUFFISANCE RENALE (METHOD FOR TREATING RENAL FAILURE) ⤷  Try a Trial
Japan 6154226 ⤷  Try a Trial
Hungary E028029 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
Harvard Business School
Merck
McKesson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.